New Bone Therapeutics Phase II Trial of ALLOB for Severe Osteoporosis

Bone Therapeutics is planning a Phase II trial with ALLOB® allogeneic “off the shelf” bone cell therapy for the treatment of severe osteoporosis.

The trial supplants a previous Phase IIA trial of PREOB® autologous therapy for the same indication. Company leadership noted that ALLOB presents advantages in dosing, logistics and scalability,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us